Eli Lilly CEO tells CNBC one-third of new GLP-1 pill patients are taking Foundayo, as drugmaker ramps up production

Eli Lilly's CEO announcement that one-third of new patients taking the company's GLP-1 pill are being prescribed its recently launched medication, Foundayo, suggests a strong start for the new product. This is significant as GLP-1 receptor agonists have become increasingly popular for treating type 2 diabetes and obesity. The fact that Foundayo is already capturing a substantial share of new patients indicates that it is likely to be a major player in the market.

The company's ramp-up of production is also noteworthy, as it indicates that Eli Lilly is preparing for strong demand. This is not surprising, given the growing demand for GLP-1 receptor agonists and the company's existing presence in the diabetes treatment market with products like Trulicity. The increased production will likely help Eli Lilly maintain its market share and meet the growing demand for its products.

Going forward, investors and industry observers will be watching to see if Eli Lilly can sustain this momentum and maintain its market share in the face of competition from other pharmaceutical companies, such as Novo Nordisk, which also has a GLP-1 receptor agonist on the market. Additionally, updates on the company's production capacity and any potential supply chain issues will be closely monitored, as they could impact the company's ability to meet demand and achieve its growth targets.

Originally reported by cnbc.com. Trade-News adds analysis for finance & markets readers.